University of Glasgow

A p-adaptive, implicit-explicit mixed finite element method for diffusion-reaction problems (2022) Wakeni MF, Aggarwal A, Kaczmarczyk Ł, McBride AT, Athanasiadis I, Pearce CJ, Steinmann P Journal article Roadmap on Spin-Wave Computing (2022) Chumak AV, Kabos P, Wu M, Abert C, Adelmann C, Adeyeye A, Akerman J, et al. Journal article Apremilast inhibits inflammatory osteoclastogenesis (2022) Degboe Y, Sunzini F, Sood S, Bozec A, Sokolova M, Zekovic A, Mcinnes IB, et al. Journal article Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation (2021) Polymeris AA, Macha K, Paciaroni M, Wilson D, Koga M, Cappellari M, Schaedelin S, et al. Journal article Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13 (2021) Zanetti C, Kumar R, Ender J, Godavarthy PS, Hartmann M, Hey J, Breuer K, et al. Journal article Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis (2021) Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G, Pricop L, et al. Journal article Predictors of blood pressure response after renal denervation beyond pretreatment blood pressure (2021) Schmieder R, Delles C, Lauder L, Ott C, Boehm M, Mahfoud F Conference contribution Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study (2021) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease P, Shawi M, Cua D, et al. Conference contribution Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study (2021) Mease P, Deodhar A, Merola J, Mcinnes I, Assudani D, Bajracharya R, Coarse J, et al. Conference contribution